CEO Nevan Charles Elam was paid $2,851,109 in fiscal year 2025, ↑ up 139.0% from fiscal year 2024 (SEC filing 0001104659-25-097509 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,851,109 ↑ Nevan Charles Elam total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nevan Charles Elam | $610,825 | $451,662 | $1,767,204 | $0 | $0 | $0 | $21,418 | $2,851,109 |
| Chief Executive Officer | ||||||||
| Daron Evans | 421,458 | 231,112 | 1,016,452 | 0 | 0 | 0 | 46,639 | 1,715,661 |
| Chief Financial Officer | ||||||||
| Brian Roberts | 483,361 | 221,988 | 667,202 | 0 | 0 | 0 | 62,177 | 1,434,728 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Nevan Charles Elam | $2,851,109 | $1,192,700 | — | ↑ +1,658,409 |
| Daron Evans | 1,715,661 | 384,065 | — | ↑ +1,331,596 |
| Brian Roberts | 1,434,728 | 817,959 | — | ↑ +616,769 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Rezolute's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper RZLT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name RZLT as a peer is temporarily unavailable — recheck shortly.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Brian Roberts | Chief Medical Officer | $1,434,728 |
| Daron Evans | CFO | $1,715,661 |
| Nevan Charles Elam | CEO | $2,851,109 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Erik Harris | Independent Director | $136,920 |
| Gil Labrucherie | Independent Director | $296,158 |
| Nerissa Kreher | Independent Director | $285,158 |
| Philippe Fauchet | Independent Director | $289,658 |
| Wladimir Hogenhuis | Independent Director | $293,658 |
| Young-Jin Kim | Director | $267,158 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Nevan Charles Elam | Director | 2025-11-19 | A | 317,000 | $0 | $0 | Common | Form 4 ↗ |
| Young-Jin Kim | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Erik Harris | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Wladimir Hogenhuis | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wladimir Hogenhuis | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Nerissa Kreher | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 2025-11-19 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2025-11-19 | A | 72,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2025-11-19 | A | 123,000 | 0 | 0 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-11-19 | A | 63,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 2025-11-19 | A | 32,000 | 0 | 0 | Common | Form 4 ↗ |
| Gil Labrucherie | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gil Labrucherie | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Nevan Charles Elam | Director | 2025-11-19 | A | 186,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-11-19 | A | 107,000 | 0 | 0 | Common | Form 4 ↗ |
| Philippe Fauchet | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Philippe Fauchet | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Young-Jin Kim | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Erik Harris | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nerissa Kreher | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-12-15 | A | 2,500 | 2 | 4,475 | Common | Form 4 ↗ |
| Nevan Charles Elam | Director | 2025-12-15 | A | 32,000 | 2 | 50,880 | Common | Form 4 ↗ |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 2025-12-15 | A | 12,000 | 2 | 19,439 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-12-15 | A | 2,500 | 2 | 4,463 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-12-15 | A | 40,000 | 2 | 70,640 | Common | Form 4 ↗ |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 2025-12-15 | A | 100 | 2 | 160 | Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2025-12-16 | A | 28,000 | 2 | 47,600 | Common | Form 4 ↗ |
| Wladimir Hogenhuis | Director | 2025-12-16 | A | 5,650 | 2 | 9,549 | Common | Form 4 ↗ |
| Nevan Charles Elam | Director | 2026-03-02 | D | 27,618 | 3 | 82,578 | Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2026-03-02 | D | 11,439 | 3 | 34,203 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2026-03-02 | D | 11,438 | 3 | 34,200 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2026-03-30 | A | 10,000 | 3 | 28,500 | Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2026-07-02 | D | 3,062 | 5 | 15,279 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2026-07-02 | D | 3,062 | 5 | 15,279 | Common | Form 4 ↗ |
| Nevan Charles Elam | Director | 2026-07-02 | D | 8,004 | 5 | 39,940 | Common | Form 4 ↗ |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 2026-09-02 | D | 2,267 | 5 | 10,202 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brian Roberts | RSU | — | — | — | — | — | $667,202 |
| Nevan Charles Elam | RSU | — | — | — | — | — | 1,767,204 |
| Daron Evans | RSU | — | — | — | — | — | 1,016,452 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brian Roberts | $667,202 | $0 | $0 | 0.0% |
| Nevan Charles Elam | 1,767,204 | 0 | 0 | 0.0% |
| Daron Evans | 1,016,452 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brian Roberts | Option | 15,000 | 4.39 | — |
| Nevan Charles Elam | Option | 106,667 | 4.61 | — |
| Daron Evans | Option | 40,000 | 4.61 | — |
| Brian Roberts | RSU | 77,000 | — | 343,420 |
| Daron Evans | RSU | 102,395 | — | 332,605 |
| Brian Roberts | RSU | 26,000 | — | 115,960 |
| Daron Evans | RSU | 103,000 | — | 459,380 |
| Daron Evans | Option | 100,000 | 4.79 | — |
| Nevan Charles Elam | Option | 179,445 | 1.02 | — |
| Nevan Charles Elam | RSU | 272,000 | — | 1,213,120 |
| Nevan Charles Elam | RSU | 204,000 | — | 909,840 |
| Brian Roberts | RSU | 103,000 | — | 459,380 |
| Daron Evans | RSU | 77,000 | — | 343,420 |
| Nevan Charles Elam | RSU | 68,000 | — | 303,280 |
| Daron Evans | RSU | 26,000 | — | 115,960 |
| Nevan Charles Elam | Option | 650,000 | 3.4 | — |
| Nevan Charles Elam | Option | 40,000 | 4.39 | — |
| Brian Roberts | Option | 175,000 | 3.4 | — |
| Brian Roberts | Option | 68,612 | 1.02 | — |
| Brian Roberts | Option | 40,000 | 4.61 | — |
| Daron Evans | Option | 177,605 | 1.02 | — |
| Daron Evans | Option | 15,000 | 4.39 | — |
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gil LabrucherieIndependent · Audit · Compensation · Nominating/Governance | $74,000 | $157,065 | $65,093 | — | $0 | $296,158 |
| Wladimir HogenhuisIndependent · Compensation (Chair) · Audit · Nominating/Governance | 71,500 | 157,065 | 65,093 | — | 0 | 293,658 |
| Philippe FauchetIndependent · Audit · Compensation · Nominating/Governance | 67,500 | 157,065 | 65,093 | — | 0 | 289,658 |
| Nerissa KreherIndependent · Audit · Compensation · Nominating/Governance | 63,000 | 157,065 | 65,093 | — | 0 | 285,158 |
| Young-Jin KimNot independent · Nominating/Governance · Compensation · Audit | 45,000 | 157,065 | 65,093 | — | 0 | 267,158 |
| Erik HarrisIndependent · Audit · Compensation · Nominating/Governance · Newly elected | 11,250 | 0 | 125,670 | — | 0 | 136,920 |
| Nevan Charles ElamEmployee director · Board Chair | — | — | — | — | — | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 11,000 / 11,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $332,250 |
| Equity awards (grant-date value) | $785,325 |
| All other compensation | $0 |
| Total cost of the board | $1,117,575 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rezolute | 2025 | Nevan Charles Elam | $610,825 | $1,767,204 | $0 | $0 | $2,851,109 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Nevan Charles Elam | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Executive Compensation”. As printed: 2,851,109. Filing ↗ |
| 2 | Section 01, Daron Evans | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Executive Compensation”. As printed: 1,715,661. Filing ↗ |
| 3 | Section 01, Brian Roberts | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Executive Compensation”. As printed: 1,434,728. Filing ↗ |
| 4 | Section 03, Brian Roberts RSU | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t83 · r5 · c11 · span 421763–421770 |
| 5 | Section 03, Nevan Charles Elam RSU | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t83 · r3 · c11 · span 412169–412178 |
| 6 | Section 03, Daron Evans RSU | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t83 · r7 · c11 · span 431373–431382 |
| 7 | Section 07, pay ratio | 10-K | 2025-09-17 | 0001104659-25-090848 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Gil Labrucherie | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 296,158. Filing ↗machine: span 201048–201221 |
| 9 | Section 08, Wladimir Hogenhuis | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 293,658. Filing ↗machine: span 209040–209213 |
| 10 | Section 08, Philippe Fauchet | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 289,658. Filing ↗machine: span 206317–206490 |
| 11 | Section 08, Nerissa Kreher | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 285,158. Filing ↗machine: span 203767–203940 |
| 12 | Section 08, Young-Jin Kim | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 267,158. Filing ↗machine: span 211587–211760 |
| 13 | Section 08, Erik Harris | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 136,920. Filing ↗machine: span 198499–198672 |
| 14 | Section 08, Nevan Charles Elam | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 02, Nevan Charles Elam 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001294 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Young-Jin Kim 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001283 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Erik Harris 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001286 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Wladimir Hogenhuis 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001288 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Wladimir Hogenhuis 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001288 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Nerissa Kreher 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001290 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Sunil Ratilal Karnawat 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Brian Roberts 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Brian Roberts 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Daron Evans 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001292 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Sunil Ratilal Karnawat 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Gil Labrucherie 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001279 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Gil Labrucherie 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001279 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Nevan Charles Elam 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001294 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Daron Evans 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001292 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Philippe Fauchet 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001281 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Philippe Fauchet 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001281 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Young-Jin Kim 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001283 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Erik Harris 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001286 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Nerissa Kreher 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001290 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Daron Evans 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001424 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Nevan Charles Elam 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001423 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Sunil Ratilal Karnawat 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001421 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Daron Evans 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001424 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Daron Evans 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001424 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Sunil Ratilal Karnawat 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001421 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Brian Roberts 2025-12-16 | Form 4 | 2025-12-17 | 0000912282-25-001427 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Wladimir Hogenhuis 2025-12-16 | Form 4 | 2025-12-17 | 0000912282-25-001429 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Nevan Charles Elam 2026-03-02 | Form 4 | 2026-03-04 | 0000912282-26-000410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Brian Roberts 2026-03-02 | Form 4 | 2026-03-04 | 0000912282-26-000412 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Daron Evans 2026-03-02 | Form 4 | 2026-03-04 | 0000912282-26-000411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Daron Evans 2026-03-30 | Form 4 | 2026-03-31 | 0000912282-26-000533 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Brian Roberts 2026-07-02 | Form 4 | 2026-07-07 | 0000912282-26-000936 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Daron Evans 2026-07-02 | Form 4 | 2026-07-07 | 0000912282-26-000929 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Nevan Charles Elam 2026-07-02 | Form 4 | 2026-07-07 | 0000912282-26-000930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Sunil Ratilal Karnawat 2026-09-02 | Form 4 | 2026-09-03 | 0000912282-26-001216 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 52 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 53 | Section 09b board cost (computed) | Computed | — | — | Cash 332,250 + equity 785,325 + all other 0 = 1,117,575, summed across the director compensation table rows.machine: formula: Σ = 1,117,575 |
| 54 | Rezolute (subject), Section 10b CEO total | DEF 14A | 2025-10-07 | 0001104659-25-097509 | CEO total compensation as printed in Rezolute's own proxy. As printed: 2,851,109. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.